
Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naïve and BTK inhibitor–treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naïve and BTK inhibitor–treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Seth Martin, MD, MHS, discusses a simplified machine learning equation that helps labs deliver more accurate LDL-C results at no cost.

Deepika Nayyar outlines how HMH built a multidisciplinary drug diversion prevention program and shares the core elements any institution needs to detect and respond to diversion effectively.

Pharmacists can use motivational interviewing as a technique to encourage influenza vaccination.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

The review combines mechanistic and real-world evidence to guide health care professionals through different scenarios in the MS treatment space.

Brendon Neuen, PhD, MBBS, discusses findings from the FIND-CKD study showing that finerenone benefits patients with nondiabetic chronic kidney disease (CKD) and glomerular disease, as well as those receiving combination SGLT2i therapy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium, for up to 12 hours of relief from minor aches and pains in patients 12 years and older.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

A yearlong trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses where VER-01 could fit within chronic pain management and why advances in standardized cannabinoid therapies may represent a pivotal moment for the future of evidence-based cannabis-derived medicines.

Federal guidelines and clinical evidence suggest that doubling or even tripling up on shots is not only safe but is also a best practice.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what the phase 3 data reveal about VER-01's potential and explains how pharmacists could help integrate standardized cannabinoid therapies into evidence-based chronic pain management.

Five consistent habits—not stock-picking or complex strategies—separate pharmacists who quietly build multi-million-dollar net worths from those who don't.

The autoinjector provides an accessible, at-home option for patients with chronic kidney disease or heart failure who need treatment for fluid buildup.

Flu vaccine rates are lagging as hesitancy rises, but community pharmacists boost vaccination with trusted counseling, easy access, and outreach.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, explains how VER-01 differs from dispensary cannabis products, emphasizing the importance of pharmaceutical standardization, consistent dosing, and rigorous clinical evaluation.

GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what sets VER-01 apart from previous cannabis-derived therapies, why it has generated significant interest in chronic pain research, and how its standardized pharmaceutical approach could shape the future of evidence-based pain management.

Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.

Australian trial shows bivalent mRNA COVID-19 booster lifts antibodies more than protein vaccine, yet both cut infection similarly over 12 months.

The pharmacist’s role is transforming from product management to clinical specialization.

As 2026 wildfire smoke from Canada blankets the US, pharmacists can facilitate early refills, counsel on protective measures, and help patients understand when worsening symptoms require emergency care.

Robert J. DiDomenico, PharmD, FAHA, discusses the new AHA scientific statement on identifying and safely deprescribing unnecessary medications in patients with cardiovascular disease.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, explains the staffing, infrastructure, hospital partnerships, and scheduling strategies needed to safely deliver outpatient CAR T-cell therapy in a community oncology setting.

Pharmacists’ individual knowledge of patient circumstances can be their greatest tool.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, RPh, MS, MCST, discusses how VER-01 could reshape the role of cannabis-derived medicines in chronic pain care, the evolving role of pharmacists, and why pharmaceutical cannabinoids and whole-plant cannabis should be viewed as complementary therapeutic options rather than competitors.

Influenza vaccination preparation should be on the docket for any pharmacy, and it isn’t too early to start now.